A
Arvind Narayana
Researcher at Tufts University
Publications - 4
Citations - 366
Arvind Narayana is an academic researcher from Tufts University. The author has contributed to research in topics: Transthyretin & Internal medicine. The author has an hindex of 2, co-authored 2 publications receiving 321 citations.
Papers
More filters
Journal ArticleDOI
Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations.
Robert H. Dworkin,Dennis C. Turk,Sarah Peirce-Sandner,Ralf Baron,Nicholas Bellamy,Laurie B. Burke,Amy S. Chappell,Kevin Chartier,Charles S. Cleeland,Ann Costello,Penney Cowan,Rozalina Dimitrova,Susan S. Ellenberg,John T. Farrar,Jacqueline A. French,Ian Gilron,Sharon Hertz,Alejandro R. Jadad,Gary W. Jay,Jarkko Kalliomäki,Nathaniel P. Katz,Robert D. Kerns,Donald C. Manning,Michael P. McDermott,Patrick J. McGrath,Arvind Narayana,Linda Porter,Steve Quessy,Bob A. Rappaport,Christine Rauschkolb,Bryce B. Reeve,Thomas Rhodes,Cristina Sampaio,David M. Simpson,Joseph W. Stauffer,Gerold Stucki,Jeffrey Tobias,Richard E. White,James Witter +38 more
TL;DR: In this paper, the authors present recommendations for the major components of confirmatory chronic pain clinical trials, including participant selection, trial phases and duration, treatment groups and dosing regimens, and types of trials.
Journal ArticleDOI
National Breakthrough Pain Study: prevalence, characteristics, and associations with health outcomes.
Arvind Narayana,Nathaniel P. Katz,Alicia C. Shillington,Judith J. Stephenson,Qing Harshaw,Carla B. Frye,Russell K. Portenoy +6 more
TL;DR: In this population of community-dwelling patients with opioid-treated chronic pain, BTP was highly prevalent and associated with negative outcomes, and the need for specific treatment plans is suggested.
Journal ArticleDOI
Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update
Thomas H. Brannagan,Teresa Coelho,Annabel K. Wang,Michael Polydefkis,Peter J. Dyck,John L. Berk,Brian M. Drachman,Peter D. Gorevic,Carol J. Whelan,Isabel Conceição,Violaine Planté-Bordeneuve,Giampaolo Merlini,Laura Obici,Josep Maria Campistol Plana,Josep Gamez,Arnt V. Kristen,Anna Mazzeo,Luca Gentile,Arvind Narayana,Kemi Olugemo,Peter Aquino,Merrill D. Benson,Morie A. Gertz +22 more
TL;DR: In this article , an antisense oligonucleotide inhibitor of hepatic transthyretin amyloidosis (hATTR/ATTRv) was used in the NEURO-TTR (NCT01737398) study.
Journal ArticleDOI
Three Newly Recognized Likely Pathogenic Gene Variants Associated with Hereditary Transthyretin Amyloidosis
Jignesh Patel,Andrew M. Rosen,Adam C. Chamberlin,B. Feldmann,Christian Antolik,Heather Zimmermann,Tami Johnston,Arvind Narayana +7 more
TL;DR: The Akcea/Ambry VUS Initiative is dedicated to gathering molecular, clinical, and inheritance data for each TTR VUS identified by genetic testing programs to reclassify TTR variants to a clinically actionable status (e.g., variant likely pathogenic [VLP]) where appropriate as discussed by the authors .